Parkinson's Disease Clinical Trials (Not Enrolling)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants
Principal Investigator: Marta San Luciano, MD, MS
Study Contact: Ananth Mahes, [email protected]
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Principal Investigator: Joshua Woolley, MD, PhD
Study Contact: Ellen Bradley, MD, [email protected]
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Principal Investigator: Jill Ostrem, MD
Study Contact: Jennifer Zhu, [email protected]
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD)
Principal Investigator: Jill Ostrem, MD
Study Contact: Eda Yilmaz, [email protected]
Closed Loop Deep Brain Stimulation in Parkinson's Disease (Summit RC+S)
Principal Investigator: Philip Starr, MD, PhD
Study Contact: Amelia Hahn, [email protected]
Adaptive Cortical and Subcortical Brain Stimulation to Improve Motor Behaviors and Gait in Parkinson's Disease
Principal Investigator: Doris Wang, MD, PhD
Study Contact: Jannine Balakid, [email protected]
Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia (Activa PC+S)
Principal Investigator: Philip Starr, MD, PhD
Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients
Principal Investigator: Philip Starr, MD, PhD
Implantable Neurostimulator for the Treatment of Parkinson's Disease (INTREPID)
Principal Investigator: Jill Ostrem, MD
Mindfulness-based Cognitive Therapy for People With Parkinson's Disease and Caregivers
Principal Investigator: Andreea Seritan, MD
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease
Principal Investigator: Paul Larson, MD
The Parkinson's Progression Markers Initiative (PPMI)
Principal Investigator: Caroline Tanner, MD, PhD
A Multicenter, Prospective, Longitudinal, Digital Assessment Study of Disease Progression in Subjects With Early, Untreated Parkinson Disease (WATCH-PD)
Principal Investigator: Caroline Tanner, MD, PhD
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension (PASADENA)
Principal Investigator: Caroline Tanner, MD, PhD
A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Principal Investigator: Chadwick Christine, MD